{"commentary":{"count":62,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":32,"podcast":24,"x_thread":6},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04666038\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"BRUIN CLL-321","nct_id":"NCT04666038","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=bruin-cll-321-nct04666038. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"BRUIN CLL-321","arms":[{"description":"Participants received 200 milligrams (mg) of pirtobrutinib administered orally once daily (QD) on Days 1 through 28 of a 28-day cycle. The treatment was continued until progressive disease, a discontinuation criterion, or unacceptable toxicity.","label":"Arm A - Pirtobrutinib","type":"EXPERIMENTAL"},{"description":"Participants received either 150 mg of idelalisib administered twice-daily (BID) orally on Days 1 through 28 of a 28-day cycle in combination with 375 milligram per square meter (mg/m\\^2) of rituximab by intravenous (IV) infusion on day 1 of cycle 1, then 4 IV infusions of rituximab 500 mg/m\\^2 every 2 weeks (Q2W) and 3 IV infusions of rituximab 500 mg/m\\^2 every 4 weeks (Q4W) or 70 mg/m\\^2 of bendamustine administered IV on day 1 and 2 of each 28-day cycle from cycles 1 to 6 in combination with 375 mg/m\\^2 of rituximab IV on day 1 of cycle 1, then 500 mg/m\\^2 of rituximab on day 1 of each 28-day cycle from cycles 2 to 6.","label":"Arm B - Idelalisib plus Rituximab or Bendamustine plus Rituximab","type":"ACTIVE_COMPARATOR"}],"collaborators":["Eli Lilly and Company"],"completion_date":{"date":"2027-05","type":"ESTIMATED"},"conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"enrollment":{"count":238,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pirtobrutinib","type":"DRUG"},{"name":"Idelalisib","type":"DRUG"},{"name":"Bendamustine","type":"DRUG"},{"name":"Rituximab","type":"DRUG"}],"last_update":"2026-04-24","lead_sponsor":"Loxo Oncology, Inc.","official_title":"A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2023-08-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC)","timeFrame":"Randomization to Disease Progression or Death Due to Any Cause (Up to 29 Months)"}],"references":[{"citation":"Loubert A, Creel K, Bhandari NR, Hess LM, Ruppert AS, Abada P, Regnault A, Payakachat N. Psychometric analysis of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library. J Patient Rep Outcomes. 2026 Jun 22;10(1):109. doi: 10.1186/s41687-026-01126-w.","pmid":"42329537","type":"DERIVED"},{"citation":"Sharman JP, Munir T, Grosicki S, Roeker LE, Burke JM, Chen CI, Grzasko N, Follows G, Matrai Z, Sanna A, Qiu L, Feng R, Hua VM, Jurczak W, Ritgen M, Yi S, Bosch F, Coombs CC, Bao K, Patel V, Liu B, Compte L, Guntur A, Wang DY, Hill M, Leow CC, Ghia P, Barr PM. Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321). J Clin Oncol. 2025 Aug;43(22):2538-2549. doi: 10.1200/JCO-25-00166. Epub 2025 Jun 6.","pmid":"40479620","type":"DERIVED"}],"start_date":{"date":"2021-03-09","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","url":"https://clinicaltrials.gov/study/NCT04666038"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/bruin-cll-321-nct04666038"}